Last reviewed · How we verify
cisplatin + capecitabine
Cisplatin crosslinks DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase, together blocking cancer cell division and survival.
Cisplatin crosslinks DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase, together blocking cancer cell division and survival. Used for Metastatic gastric cancer, Metastatic esophageal cancer, Advanced biliary tract cancer.
At a glance
| Generic name | cisplatin + capecitabine |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Chemotherapy combination (platinum agent + antimetabolite) |
| Target | DNA (cisplatin); thymidylate synthase (capecitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that forms covalent DNA adducts, causing interstrand and intrastrand crosslinks that prevent DNA replication and transcription. Capecitabine is a prodrug of fluorouracil that inhibits thymidylate synthase, disrupting nucleotide synthesis and DNA replication. The combination provides synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Metastatic gastric cancer
- Metastatic esophageal cancer
- Advanced biliary tract cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Diarrhea
- Hand-foot syndrome
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
Key clinical trials
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (PHASE2)
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer (PHASE3)
- Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (PHASE3)
- A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT) (PHASE2)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cisplatin + capecitabine CI brief — competitive landscape report
- cisplatin + capecitabine updates RSS · CI watch RSS
- AstraZeneca portfolio CI